Pierre Tariot

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.